A Blockade, Oracle Up 11%, and Monday Did Not Come Up for Air

Monday opened with a naval blockade, $99 oil, and futures pointing south.

It closed with the S&P 500 briefly positive for 2026, Oracle up 11% at an AI summit, Bitcoin back at $72,000, and Revolution Medicines announcing a pancreatic cancer trial result that stopped analysts mid-sentence. Keep reading.

Right now, one company is quietly powering critical operations across the U.S. military.

That company is SpaceX.

But the real story may be what happens next.

There’s growing speculation that Elon Musk could bring SpaceX public in the future.

Events like this don’t happen often—and when they do, early access matters.

Some believe this could be one of the biggest investment opportunities of the decade.

Learn how to position ahead of it

The major indexes recovered and closed higher after Trump said Iran had reached out and wanted a deal badly, with the S&P 500 briefly turning positive for 2026 in midday trading.

Oil settled near $99 a barrel as the blockade removed roughly 2 million barrels of daily Iranian exports from an already constrained market.

Tech led the recovery, with Oracle jumping 11% at its AI summit and Bitcoin bouncing back to $72,000 on Senate Clarity Act optimism.

The session closed with the market betting that the blockade is a pressure tactic rather than a permanent escalation, and the next few days will tell you whether that bet holds.

Delta Air Lines (NYSE: DAL) just revealed its first major upgrade to its Delta One suite in nearly a decade, and this is more than just a nicer seat. The airline is clearly leaning into a future in which premium travelers drive a larger share of the business.

The Focus Is Shifting Upwards

For a long time, airlines chased volume by filling as many economy seats as possible.

That approach is slowly giving way to a different mindset where fewer passengers can still mean better results if they are paying more.

If you think about it from a business perspective, Delta is prioritizing value per seat rather than just volume per flight.

When The Product Is the Experience

The new suites come with longer beds, more personal space, and a design that is clearly built around comfort for long-haul travel.

These are not random upgrades; they are meant to make the premium cabin feel like a completely different tier of travel.

This is where your expectations start to shift, because once airlines elevate comfort at the top, the gap between classes becomes much more noticeable.

What This Really Signals

What stands out is how intentional this move feels from Delta’s side. The airline is clearly betting that premium demand will keep growing and is building its product around that belief.

If that bet plays out, flying might feel less like one experience and more like two completely different worlds, depending on what you are willing to pay.

CollPlant Biotechnologies (NASDAQ: CLGN) just lost its development deal with AbbVie, and that is a much bigger hit than it looks on the surface.

The partnership was central to advancing one of its key products, and without it, the company would be forced to rethink its path forward almost immediately.

This Changes the Entire Game Plan

Biotech companies rely heavily on partnerships to fund development and move products toward commercialization.

Losing a partner like AbbVie means losing not just funding, but also validation and momentum in a competitive space.

If you think about it, CollPlant is now back to having to prove its technology all over again.

The Cost Cuts Tell You Everything

Cutting 50% of the workforce is not about efficiency; it is about survival and extending time. The company is trying to stretch its runway long enough to secure a new partner or push its products further along.

This is where your understanding shifts: the focus is no longer growth; it is staying alive long enough to find the next opportunity.

Now It Is a Race Against Time

CollPlant is already in talks with potential partners, which is the only real path forward from here. For you, the key is whether the company can replace AbbVie with someone equally committed.

CollPlant still has its technology and pipeline, but now everything depends on execution, partnerships, and whether it can rebuild momentum before time runs out.

Elon Musk’s Starlink is rumored to be heading for a $100 billion IPO — potentially dwarfing Amazon’s IPO by 228X.

Most people assume opportunities like this are reserved for Wall Street insiders… but James Altucher has revealed a way for everyday investors to get in early.

He’s even giving out a FREE ticker symbol for those who want a piece of the action.

Discover it here before it’s too late

Lululemon Athletica (NASDAQ: LULU) is now facing an investigation into whether its products meet the safety and health standards it promotes.

This is not just a routine issue; it goes straight to the foundation of how the brand positions itself.

The company is not just selling clothing; it is selling a lifestyle built around wellness and trust.

This Cuts Right Into the Brand Story

Lululemon has spent years building an image around quality, performance, and health-conscious design. If questions start to form about what goes into its products, that image can shift quickly.

That matters more than anything else, because perception is what allows the brand to charge premium prices.

Customers are not just buying leggings or workout gear; they are buying into a belief that the product aligns with a healthier lifestyle. Once that belief is questioned, it creates hesitation that no marketing campaign can instantly fix.

This Is a Reputation Test, Not Just an Investigation

What stands out to you is how exposed a brand like Lululemon is in moments like this.

It has built its identity on trust and wellness, which makes any doubt far more damaging than it would be for a regular apparel company.

And once that kind of question enters the conversation, the brand has to work twice as hard to maintain its image.

👉 Click here to get our closing report to your cell for free!

Real Messenger [RMSG] $2.40 (+411.18%)

Real Messenger is a chat-based real estate tech platform with over 1 million users across 35 countries.

The stock has been running on a March 25 MOU with a publicly traded U.S. brokerage to potentially deploy its CRM, messaging, and listings platform across the brokerage's entire agent network.

That partnership news, combined with a Nasdaq compliance deadline that requires RMSG to trade above $1 to avoid delisting, created a short squeeze on 454x average volume.

Aeluma [ALMU] $15.71 (+46.00%)

The U.S. government awarded Aeluma $4 million in contracts Monday to scale its quantum dot laser and AlGaAs photonics platform, with Tower Semiconductor and Sumitomo already locked in as partners.

This is non-dilutive government validation for a $275 million company with a clear path to commercialization across AI infrastructure, defense, and quantum.

The funding removes the central risk that was keeping institutional buyers on the sidelines.

Revolution Medicines [RVMD] $135.25 (+40.26%)

Daraxonrasib hit every mark in the Phase 3 RASolute 302 trial, delivering a median overall survival of 13.2 months versus 6.7 months on chemotherapy in pancreatic cancer.

Revolution files for FDA approval under a priority voucher.

At $26.8 billion, this is the defining RAS oncology asset on the market, and Monday’s all-time high is the correct response to a result of this magnitude.

Children’s Place [PLCE] $2.91 (-26.70%)

Q4 revenue came in at $329 million, down 19% year over year and $37 million below estimates, with an EPS miss of $1 per share.

This is not a turnaround playing out slowly; it is a deterioration story on a stock already trading near its 52-week low.

Until revenue stabilizes, every quarterly print reprices the stock lower, and Friday’s report gave the market plenty of reasons to keep selling today.

Greenland Energy [GLND] $6.30 (-17.97%)

Greenland Energy published a promotional editorial via NetworkNewsWire on energy security and Arctic drilling.

The problem: this stock has dropped on every single piece of positive news since listing in late March, falling 37% on a drilling agreement and dropping again on a second editorial last week.

This is a pure sentiment vehicle with no operating history, and today’s selloff fits the established pattern perfectly.

Zentalis Pharmaceuticals [ZNTL] $5.59 (-15.45%)

Zentalis surged 51% on Thursday and Friday after announcing the pivotal dose selection for azenosertib in ovarian cancer.

Monday’s 17% drop is the standard hangover from a one-session rocket in a thin-float biotech.

There is no new negative catalyst; the DENALI topline readout is still on track for year-end 2026. This is profit-taking, not a reversal of the thesis.

The conflict in Iran isn’t slowing down—it’s intensifying.

Ongoing strikes and pressure on global oil routes are already pushing gas prices higher, with analysts warning of broader economic impact if disruptions continue.

That kind of instability can affect portfolios tied to traditional assets. It’s why many investors look to physical gold as a way to help protect their savings during uncertain times.

Red State Gold Group’s FREE Gold IRA Guide shows how eligible IRA or 401(k) funds can be rolled into physical gold and silver.

Get your free guide today

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.